Trials / Terminated
TerminatedNCT04536077
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDX-301 | The drug will be supplied free of charge by Celldex |
| DRUG | CDX-1140 | The drug will be supplied free of charge by Celldex |
| PROCEDURE | Research blood draw | At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery |
Timeline
- Start date
- 2021-08-13
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
- First posted
- 2020-09-02
- Last updated
- 2024-10-08
- Results posted
- 2024-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04536077. Inclusion in this directory is not an endorsement.